ProCE Banner Activity

ExpressPoints
A Review of Current and Emerging Treatment Options for Myelodysplastic Syndromes

Slideset Download
Download this summary slideset from a live webinar for the latest evidence on treatment approaches for lower-risk, higher-risk, and relapsed/refractory MDS.

Released: December 23, 2021

Expiration: December 22, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Gamida Cell Ltd

Geron

Gilead Sciences, Inc.

Karyopharm Therapeutics Inc.

Takeda Pharma USA Inc Takeda Onc Co

Program Director Disclosure

Program Director

Michael R. Savona, MD, FACP

Director of Leukemia Research
Senior Investigator, Hematologic Malignancies Research and Drug Development
Sarah Cannon Research Institute
Sarah Cannon Center for Blood Cancers
Tennessee Oncology
Nashville, Tennessee

Michael J. Savona, MD, has disclosed that he has received consulting fees from AbbVie, BMS, CTI, Geron, Karyopharm, Novartis, Ryvu, Sierra Oncology, Taiho, Takeda, and TG Therapeutics; has received research support from Astex, ALX Oncology, Incyte, Takeda, and TG Therapeutics; and has ownership interest in Karyopharm and Ryvu.

Faculty Disclosure

Primary Author

Jacqueline S. Garcia, MD

Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts 

Jacqueline S. Garcia, MD, has disclosed that she has received consulting fees from AbbVie, Astellas, and Takeda and research support from AbbVie, AstraZeneca, Genentech, Pfizer, and Prelude.

Amer Zeidan, MBBS, MHS

Professor of Internal Medicine
Chief, Division of Hematologic Malignancies
Assistant Medical Director, Hematology Clinical Trials Office (CTO)
Director, Hematology Early Therapeutics Research
Director, Leukemia and Myeloid Malignancies Program
Co-Leader, Leukemia and Myeloid Malignancies Clinical Research Team (CRT)
Section of Medical Oncology and Hematology, Department of Internal Medicine
Yale School of Medicine and Yale Comprehensive Cancer Center
New Haven, Connecticut

Amer Zeidan, MBBS, has disclosed that he has received funds for research support from AbbVie, ADC Therapeutics, Amgen, Aprea, Astex, Boehringer Ingelheim, Cardiff Oncology, Celgene/Bristol-Myers Squibb, Incyte, Medimmune/AstraZeneca, Novartis, Otsuka Pfizer, Takeda, and Trovagene and consulting fees from Acceleron, Agios, Amgen, Aprea, Astellas, Astex, BeyondSpring, Boehringer Ingelheim, Cardiff Oncology, Cardinal Health, Celgene/Bristol-Myers Squibb, Daiichi Sankyo, Epizyme, Gilead Sciences, Incyte, Ionis, Janssen, Jazz, Kura, Novartis, Otsuka, Pfizer, Seattle Genetics, Syndax, Taiho, Takeda, Trovagene, and Tyme.